Aberrant expression of HMGCS2 in pan-cancer is closely associated with clinical pathology and tumor tissue, suggesting its potential as a therapeutic target for cancer suppression, particularly in clear cell renal cell carcinoma. This evidence concerns the gene HMGCS2 and cancer.